Intravenous (IV) iron drugs market was valued at $2.82 billion in 2025 and is projected to reach $5.38 billion by 2035, registering a CAGR of 6.7% over the forecast period from 2026 to 2035. The market is experiencing significant growth driven by the high and persistent prevalence of iron deficiency and anemia globally, which increases clinical demand for effective therapeutic interventions. Iron deficiency remains the most common nutritional deficiency globally, affecting roughly one in four individuals and contributing substantially to anemia cases that require medical management beyond oral supplementation. IV iron therapies are increasingly used in settings where oral iron is ineffective, poorly tolerated, or too slow to correct severe deficiencies, such as chronic kidney disease and oncology?associated anemia. The persistent burden of anemia among vulnerable populations, including women of reproductive age and older adults, continues to expand the addressable patient base for advanced intravenous formulations, strengthening market uptake and investment. This sustained clinical need positions IV iron drugs as a critical component of anemia management strategies across healthcare systems.
Browse the full report description of “Intravenous (IV) Iron Drugs Market Size, Share & Trends Analysis Report by Product Type (Iron Dextran, Ferric Carboxymaltose, Iron Sucrose, and Ferric Gluconate), and by Application (Oncology, Nephrology, Gastroenterology, Obstetrics and Gynecology, Cardiology, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/intravenous-iv-iron-drugs-market
Global anemia remains a widespread public health challenge. According to the World Health Organization estimates, approximately 30.7% of women aged 15–49 years and 35.5% of pregnant women were affected by anemia in 2023, highlighting substantial unmet needs for effective treatment strategies. Iron deficiency is the most common underlying cause of anemia and affects nearly 2?billion people globally, creating a large potential patient pool for IV iron therapies. In the United States, CDC data show that overall anemia prevalence was 9.3% among individuals aged 2?years and older during 2021–2023, with higher rates among females (13.0%) than males (5.5%), pointing to significant demographic demand for advanced treatment modalities.
Market Coverage
Key questions addressed by the report.
Global Intravenous (IV) Iron Drugs Market Report Segment
By Product Type
By Application
Global Intravenous (IV) Iron Drugs Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/intravenous-iv-iron-drugs-market